文献速递乳腺癌

TOUCH II期试验:HR阳性/HER2阳性早期乳腺癌新辅助无化疗方案与紫杉醇比较

Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).
PubMed 文献 · Ann Oncol · 2025-10-16

TOUCH是一项国际开放标签II期试验,入组绝经后cT>1cm、cN0或cN1的HR阳性/HER2阳性乳腺癌患者,随机接受16周每周紫杉醇或哌柏西利+来曲唑,均联合曲妥珠单抗+帕妥珠单抗。主要假设RBsig与pCR存在交互作用未获支持(P=0.18),但无化疗骨架的pCR率与紫杉醇相似(33.3% vs 32.9%)。

要点

  • 哌柏西利+来曲唑+双靶向的pCR率33.3%,与紫杉醇+双靶向的32.9%相近。
  • RBsig与治疗对pCR无显著交互作用(P=0.18),主要假设未获支持。
  • 非luminal型pCR高于luminal型(45.5% vs 18.4%),与治疗无交互。

核心结论

  • 主要假设未获支持,但哌柏西利+来曲唑联合双靶向的无化疗方案pCR率与紫杉醇相似,为有吸引力的替代策略。

研究设计与样本

  • 国际、开放标签、随机II期试验,入组绝经后cT>1cm、cN0或cN1的HR阳性/HER2阳性乳腺癌患者。
  • 随机分配至16周新辅助每周紫杉醇或哌柏西利+来曲唑,均联合曲妥珠单抗+帕妥珠单抗(HP)。
  • 共147例随机(紫杉醇+HP 74例,哌柏西利+来曲唑+HP 73例),145例构成治疗人群,中位年龄69岁(IQR 63-73)。
  • 主要目标为E2F通路活性基因签名(RBsig)与pCR(ypT0N0或ypTisN0)的交互作用,采用逻辑回归在115例可评估患者中分析。

主要发现

  • pCR率在紫杉醇+HP组为32.9%(95%CI 22.3%-44.9%),在哌柏西利+来曲唑+HP组为33.3%(95%CI 22.7%-45.4%)。
  • RBsig与治疗交互作用不显著(P=0.18):紫杉醇+HP组RBsig高 vs 低pCR为31.3%(95%CI 16.1%-50.0%) vs 42.3%(95%CI 23.4%-63.1%);哌柏西利组为38.5%(95%CI 20.2%-59.4%) vs 25.8%(95%CI 11.9%-44.6%)。
  • 非luminal型 vs luminal型pCR为45.5% vs 18.4%,与治疗无交互作用。
  • 哌柏西利组完成治疗比例高于紫杉醇组(94.4% vs 79.5%)。
  • 最常见3-4级不良事件为中性粒细胞减少和腹泻:紫杉醇+HP组 vs 哌柏西利+来曲唑+HP组分别为6.9% vs 43.1%和11% vs 8.3%。

临床怎么用

  • 对于绝经后HR阳性/HER2阳性早期乳腺癌,哌柏西利+来曲唑联合双靶向可作为免化疗的新辅助治疗选择,pCR率与紫杉醇联合双靶向相当。

局限性

  • II期试验样本量有限,主要假设未达统计学显著,结果需进一步验证。
  • RBsig可评估患者为115例,并非全部随机人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a heterogeneous disease with low pathological complete response (pCR) to standard neoadjuvant treatment. Cyclin-dependent kinase 4 and 6 inhibitors with endocrine and anti-HER2 therapy have shown a potential for chemotherapy omission in this context. PATIENTS AND METHODS: TOUCH is an international, open-label, phase II trial for postmenopausal patients with cT >1 cm, cN0 or cN1, HR-positive/HER2-positive BC, randomly assigned to 16 weeks of neoadjuvant weekly paclitaxel or palbociclib and letrozole, both with trastuzumab + pertuzumab (HP). The primary objective investigated the interaction between a gene signature of E2F pathway activity (RBsig) and pCR (ypT0N0 or ypTisN0), hypothesizing higher pCR for RBsig-high tumors in the paclitaxel + HP group and for RBsig-low tumors in the palbociclib + letrozole + HP group. RBsig was assessed by RNA-sequencing from pre-treatment biopsies; intrinsic subtypes were estimated by absolute intrinsic molecular subtyping Treatment-by-biomarker interaction was estimated using logistic regression in 115 assessable patients. RESULTS: A total of 147 patients were randomly assigned (74 paclitaxel + HP, 73 palbociclib + letrozole + HP) and 145 constituted the treated population, with a median age of 69 years (interquartile range 63-73 years). More patients completed palbociclib versus paclitaxel (94.4% versus 79.5%). The most frequent grade 3-4 adverse events were neutropenia and diarrhea (6.9% versus 43.1% and 11% versus 8.3% in the paclitaxel + HP versus the palbociclib + letrozole + HP groups, respectively). The pCR rate was 32.9% [95% confidence interval (CI) 22.3% to 44.9%] in the paclitaxel + HP group and 33.3% (95% CI 22.7% to 45.4%) in the palbociclib + letrozole + HP group. No significant treatment-by-RBsig interaction was observed (P = 0.18): pCR in RBsig high versus low was 31.3% (95% CI 16.1% to 50.0%) versus 42.3% (95% CI 23.4% to 63.1%) in the paclitaxel + HP group, and 38.5% (95% CI 20.2% to 59.4%) versus 25.8% (95% CI 11.9% to 44.6%) in the palbociclib group. pCR was higher in non-luminal versus luminal subtypes (45.5% versus 18.4%), with no interaction with treatment. CONCLUSIONS: Although the primary hypothesis was not supported, TOUCH shows that dual anti-HER2 blockade with a chemotherapy-free backbone of palbociclib + letrozole yields pCR rates similar to paclitaxel, representing an attractive alternative treatment strategy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Malorni L, Tyekucheva S, Gombos A, et al. Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17). Ann Oncol. 2025. PMID: 41109527. doi:10.1016/j.annonc.2025.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。